Pilot Study to Improve Therapeutic Outcomes for Dysphagia ... · Pilot Study to Improve Therapeutic...

Pilot Study to Improve Therapeutic Outcomes for Dysphagia After Radiation

Therapy

NCT Number NCT02564887

Protocol Version ApprovedReviewed June 7 2018

1292020 httpswwwosirispitteduosirisDoc085H10C5MO114760S956EFEUC96fromStringhtml

httpswwwosirispitteduosirisDoc085H10C5MO114760S956EFEUC96fromStringhtml 254

Please select the external IRB of record

Provide the name of the Central IRB

Quality assurance projects are not subject to IRB review and approval UPMC has adopted anoversight process that requires the submission of all quality assurance projects for review AtUPMC submissions are reviewed by the Quality Improvement Review Committee (QRC)You can contact the QRC at askqrcupmcedu

Research studies that are limited to the inclusion of deceased individuals are not subject toIRB review and approval Research performed on individuals who have been declared legallydead andor research involving the collection of tissues from deceased individuals is notsubject prior review and approval by the University of Pittsburgh IRB

There are however ethical issues associated with research conducted on or involvingdeceased individuals To address these ethical issues all University faculty who desire toperform research on or involving deceased individuals must submit a project application forreview and approval by the Committee for Oversight of Research and Clinical TrainingInvolving the Dead Research Involving the Dead (CORID) Note that as per UPMC policiesresearch involving the medical records of deceased individuals is subject to obtaining thewritten consent of the decedentsrsquo next-of-kin or the executors of the decedentsrsquo estates

For studies that include BOTH living and deceased subjects IRB review and approval isrequired

Emergency Use is the use of a test article on a human subject in a life-threatening situation inwhich no standard acceptable treatment is available and in which there is not sufficient timeto obtain IRB approval [21 CFR312310] Detailed information on the submission process isavailable on the IRB website under the A-Z Guidance Emergency Use

All of the following conditions must exist to justify the emergency use of an unapprovedinvestigational drug biologic or device Check all the boxes that applySelectionsThere are no items to display



View T30

Triage Section

T30 What is the anticipated risk to the research participants

Minimal Risk

T31 Why do you feel that all aspects of this research study including screening and follow-up involve no more than minimal risk to the research subjects

The research procedures consist of the following questionnaire completion and the use of theIowa Oral Performance Instrument (IOPI) This device measures tongue strength andendurance and can also be used to exercisestrengthen the tongue and palate

T40 Does the proposed study qualify for exempt IRB review or for a determination of eithernot research or no human subject involvement

No

T50 Does the proposed research study qualify for expedited IRB review status

No

View CS010 - 0111

Cover Sheet Section

CS10 What is the reason for this submission

New Research Protocol Submission

CS11 Has this research study been approved previously by the University of PittsburghIRB

No

If the study expired you are required to upload the completed Renewal ReportForm and a Data and Safety Monitoring Report



Upload the Renewal Report Form and Data and Safety Monitoring ReportName Modified Date

Previous IRB

CS111 Has this research study (or a substantially similar research study) been previouslydisapproved by the University of Pittsburgh IRB or to your knowledge by any otherIRB

No

If Yes identify the IRB IRB number if Pitt IRB disapproved and the primary reasonsfor disapproval

View CS020 - 021

Cover Sheet Section

CS20 Title of Research Study

Pilot Study to Improve Therapeutic Outcomes for Dysphagia after RadiationTherapy

CS201 Use the textbox below to list any language or documents to be displayed in the approvalletter List only those items submitted for review with this submission

Documents to be displayed may include items such as versions of investigator brochuresconsent forms and advertisements

If specific language is not required in the approval letter leave the textbox blank (do notwrite None)

Requested approval letter wording

CS21 Research Protocol Abstract

Patients with head and neck cancer treated with chemoradiation often develop a treatmentassociated dysphagia The common complaint is foods sticking in the pharynx This studyseeks to test the Iowa Oral Performance Instrument (IOPI) in the management of treatmentinduced dysphagia following chemoradiation for oral pharyngeal laryngealhypopharyngeal cancer This pilot study seeks to compare standard exercise therapy plus



IOPI to standard exercise alone to determine if recovery is enhanced and to determine ifrate of recovery is accelerated

CS22 Select the category that best describes your research

View CS030 - 039

Cover Sheet Section

CS30 Name of the Principal Investigator

Jonas Johnson

Note Adjunct faculty of the University including lecturers and instructors are notpermitted to serve as a PI or Faculty Mentor but may serve as co-investigators Refer toChapter 4 on the HRPO website for more information

CS31 Affiliation of Principal Investigator

UPitt faculty member

If your answer was Other fill in the Principal Investigators affiliation

If you chose any of the Pitt options please indicate the specific campusMain Campus - Pittsburgh

If you chose the UPi faculty member opon provide the PIrsquos University Faculty TitleChairperson

CS311 Indicate below the name of the qualified University faculty member or UPP orUPMC staff member who will serve as a mentor and provide supervision or guidanceregarding the conduct of this research study

CS32 Address of Principal Investigator

EEI Suite 500Pittsburgh PA 15213

CS33 Recorded Primary Affiliation of the Principal Investigator

U of Pgh | School of Medicine | Otolaryngology

CS34 Identify the School Department Division or Center which is responsible foroversight of this research study




CS35 Telephone Number of Principal Investigator

412-647-2130

CS36 Recorded Current E-mail Address of Principal Investigator to which all notificationswill be sent

johnsonjtupmcedu

CS37 Fax Number

412-647-2080

CS38 Does this study include any personnel from Carnegie Mellon University andor useany CMU resources or facilities (eg Scientific Imaging and Brain Research Center(SIBR)

No

CS39 Is this your first submission as PI to the Pitt IRB

No

View CS040

Cover Sheet Section

CS40 List of Co-Investigators

Last First Organization

Coyle JamesU of Pgh | School of Health and Rehabilitation Sciences |Communication Science and Disorders

Hathaway Bridget U of Pgh | School of Medicine | OtolaryngologyKim SeungwonU of Pgh | School of Medicine | OtolaryngologySmith Libby U of Pgh | School of Medicine | OtolaryngologyWassermanTamara Physician Services Division (UPP and CMI) | UPP | Other

View CS050 - CS063

Cover Sheet Section



CS50 Name of Primary Research Coordinator

Christine Harrison

CS51 Address of Primary Research Coordinator

1400 Locust Street-Suite 2100Pittsburgh PA 15219

CS52 Telephone Number of Primary Research Coordinator

412-232-9097

CS60 Name of Secondary Research Coordinator

CS61 Address of Secondary Research Coordinator

CS62 Telephone Number of Secondary Research Coordinator

CS63 Key PersonnelSupport Staff (Only list those individuals who require access toOSIRIS) LastFirst OrganizationThere are no items to display

View CS070

Cover Sheet Section

CS70 Will this research study use any Clinical and Translational Research Center (CTRC)resources

No

CS71 Please select the sites you intend to use

There are no items to display



View CS080

Cover Sheet Section

CS80 Select the entity responsible for scientific review

Department Review - (a dean department chair division chief or center head) Note DoD funded studies require departmental review

CS81 Select the school department or division which is responsible for scientific review ofthis submission


CS81 Select the CTRC which is responsible for scientific review of this submission

View CS090 - 100

Cover Sheet Section

CS90 Does this research study involve the administration of an investigational drug or anFDA-approved drug that will be used for research purposes

No

CS91 Do you plan to utilize the Investigational Drug Service (IDS) to dispense the drug

CS100Is this research study being conducted under a University of Pittsburgh-basedsponsor-investigator IND or IDE application

No

If YES you are required to submit the IND or IDE application and all subsequent FDAcorrespondence through the Office for Investigator-Sponsored IND and IDE Support(O3IS) Refer to applicable University policies posted on the O3IS website (wwwO3ISpittedu)

CS101 Append to this application

(1) Copy of the current version of the clinical protocol submitted with the IND or IDE



application which corresponds to this IRB submission NameModified Date

(2) Copy of the FDArsquos letter which acknowledges receipt of the application and assignmentof the IND or IDE number NameModified Date

View CS110

Cover Sheet Section

CS110 Use the Add button to upload one or more of the following

the sponsor protocol (including investigator initiated studies) andorother brochuresthe multi-center protocol and consent form template if applicable

NameModified Date

Is this research study supported in whole or in part by industry This includes theprovision of products (drugs or devices) No

Is this a multi-centered study

No

View CS120 - 140

Cover Sheet Section

CS120 Does your research protocol involve the evaluation or use of procedures that emitionizing radiation

No

HUSC GUIDANCE REQUIREMENTS FOR THE REVIEW OF HUMAN SUBJECT RESEARCH

PROTOCOLS BY THE HUMAN USE SUBCOMMITTEE (HUSC) RADIATION SAFETY COMMITTEE



For Research Protocols Involving the Evaluation of Use of Diagnostic Procedures thatEmit Ionizing Radiation

Formal HUSC reviewapproval is required if the research protocol involves any of thefollowing

1 The use or evaluation of a radioactive agent or procedure that is not currentlyapproved (ie for any clinical indication) by the FDA

2 The evaluation (ie for safety andor effectiveness) of a FDA-approved

radiopharmaceutical or procedure for an ldquooff labelrdquo indication1 or the use of aFDA-approved radiopharmaceutical or procedure for an ldquooff labelrdquo indication if suchuse is experimental (ie not routinely performed in clinical practice)

3 Individuals (eg healthy volunteers) who would not be undergoing the procedure inassociation with the diagnosis or treatment of a disease or condition

Formal HUSC reviewapproval is not required if the diagnostic procedure is beingperformed in a standard clinical manner and frequency for screening or to evaluate theoutcome of a treatment regimen This would include diagnostic procedures for off- label

uses that are routinely performed in clinical practice 23

For Research Studies Involving the Use or Evaluation of Therapeutic Procedures thatEmit Ionizing Radiation

Formal HUSC reviewapproval is required if parameters (eg total radiation dose dosefractionation scheme etc) of the radiation therapy procedure(s) are defined by the researchprotocol

1An ldquooff-labelrdquo indication is a clinical indication which is not currently specified in theFDA-approved product labeling2The risks of radiation exposure associated with the diagnostic procedure must continue tobe addressed in the protocol and consent form using the HUSC-accepted wording3The University of Pittsburgh IRB at its discretion may request formal HUSC review ofthe research protocol

For any questions related to these requirements or their application contact the Chairof the HUSC (412-383-1399) or the Universityrsquos Radiation Safety Office (412-624-2728)

CS121 After reviewing the HUSC guidance above does your research protocol requireHUSC review (Note University of Pittsburghrsquos Radiation Safety Committee oversight islimited UPMC Presbyterian-Shadyside Magee Womenrsquos Hospital of UPMC Childrenrsquos



Hospital of Pittsburgh-UPMC and Hillman Cancer Center If other sites you will berequired to obtain approval from your radiation safety officer Please contactaskirbpittedu for more information)

Upload Radiation FormsName Modified Date

CS130 Does this research study involve the deliberate transfer of recombinant or syntheticnucleic acid molecules into human subjects

No

Upload Appendix M of NIH GuidelinesName Modified Date

CS140 Are you using UPMC facilities andor UPMC patients during the conduct of yourresearch study

Yes

If Yes upload completed Research Fiscal Review FormName Modified DateFRIAR IOPIdocx 922015 1144 AM

View CS150 - CS1501(a)

Cover Sheet Section

CS150 Indicate the sites where research activities will be performed andorprivate information will be obtained

Choose all sites that apply andor use Other to include sites not listedSitesUPMC

University of Pittsburgh



CampusCampusThere are no items to display

List university owned off-campus research sites if applicable

UPMC SitesUPMC PresbyterianUPMC MontefioreUPMC Shadyside

UPMC Cancer Network SitesSiteThere are no items to display

If you selected School International or Other list the sites

For research being conducted at non Pitt or UPMC sites upload asite permission letter granting the researcher permission to conducttheir research at each external siteNameModified Date

CS151 Have you Jonas Johnson verified that all members of the researchteam have the appropriate expertise credentials and if applicablehospital privileges to perform those research procedures that aretheir responsibility as outlined in the IRB protocol

Yes

CS152 Describe the availability of resources and the adequacy of thefacilities to conduct this study

The UPMC Dept of Otolaryngology treats individuals withqualifying diagnoses for this research at both UPMC Shadyside andUPMC PresbyterianMontefiore Each clinical office has board certified



clinicians in their respective fields that are extremely qualified intreating patients with swallowing difficulties Additionally clinicianshave extensive research experience Each clinic has both physicians andspeech language pathologists who will be able to identify educateenroll and implement the minimal amount of research proceduresnecessary for the conduct of this research during clinical appointmentsof potential subjects The study team has access to protected servers fordata security and information protection whenever data is generatedcollected or stored

View CS160

Cover Sheet Section

CS160 Special Research Subject Populations

CategoriesNone

View CS170

Cover Sheet Section

CS170 Does your research involve the experimental use of any type of human stem cell

No

View Clinical Trial Study

NIH Definition of a Clinical Trial

A research study1 in which one or more human subjects2 are prospectively assigned3 to

one or more interventions4 (which may include placebo or other control) to evaluate the

effects of those interventions on health related biomedical or behavioral outcomes5

1 See Common Rule definition of research at 45 CFR 46102(d)

2 See Common Rule definition of human subject at 45 CFR 46102(f)



or the specific problems or issues that will be addressed by the study)To compare standard exercise therapy plus IOPI to standard exercise alone to determine ifrecovery is enhanced and to determine if rate of recovery is accelerated

13Background Briefly describe previous findings or observations that provide thebackground leading to this proposal The IOPI device is one of the most commonly used measurement techniques available tomeasure tongue strength and endurance Some research studies have indicated that it can beused to investigate influences of age gender and medical condition on tongue strength andspeech

14Significance Why is it important that this research be conducted What gaps in existinginformation or knowledge is this research intended to fill This is a pilot study designed to look at any enhancement the IOPI device might have whenpaired with standard therapy for dysphagia following chemoradiation

View 201

Section 2 - Research and Design Methods

21 Does this research study involve the use or evaluation of a drug biological ornutritional (eg herbal or dietary) supplement

No

211 Does this research study involve an evaluation of the safety andor effectiveness of oneor more marketed nutritional (eg herbal or dietary) supplements for the diagnosisprevention mitigation or treatment of a specific disease or condition or symptomscharacteristic of a specfic disease or condition

2111List each of the marketed nutritional supplements being evaluated in this researchstudy Specify for each supplement the corresponding IND number or attach FDAcorrespondence specifying that an IND is not required

Marketed nutritional supplement IND numberThere are no items to display



Upload FDA correspondence specifying that an IND is not required if applicableNameModified DateVersion

View 202

Section 2 - Research Design and Methods

22 Will this research use or evaluate the safety andor effectiveness of one ormore devices

Yes

221 Does this research study involve an evaluation of the safety andor effectiveness of oneor more devices not currently approved by the FDA for general marketing

No

If YES describe your plan to prevent unauthorized use of the investigational device

2211List each of the unapproved devices being evaluated in this research study

Specify for each listed device the corresponding Investigational Device Exemption (IDE)number or provide a justification for why you feel that this device and its use as proposedin this research study constitute a non-significant risk (ie to include potential failure of thedevice) to the research subjects

Unapproved device IDE Non-significant risk justificationThere are no items to display

View 2022 - Involve evaluation of safteyeffectiveness of one or more devices FDA-approved


222 Does this research study involve the use or evaluation of the safety andoreffectiveness of one or more devices approved by the FDA for general marketing

Yes

2221 Does this research study involve an evaluation of one or more FDA-approved devices



for a clinical indication subject population andor operational parameter that is notspecified in the current FDA-approved product labeling for that device (ie for anldquooff-labelrdquo indication)

No

22211List each of the devices being evaluated for an ldquooff-labelrdquo indication Specify foreach listed device the corresponding Investigational Device Exemption (IDE)number for this deviceresearch study or provide a justification for why you feelthat this device and its ldquooff-labelrdquo use as proposed in this research study (ie toinclude potential failure of the device) constitute a non-significant risk to theinvolved research subjects

Device IDE Non-significant risk justificationThere are no items to display

View 203 - Summarize general classification


23 Summarize the general classification (eg descriptive experimental) andmethodological design (eg observational cross-sectional longitudinal randomizedopen-label single-blind double-blind placebo-controlled active treatment controlledparallel arm cross-over arm) of the proposed research study as applicable

Randomized observational longitudinal descriptive crossover

231Does this research study involve a placebo-controlled arm

No

View 204


24 Will any research subjects be withdrawn from known effective therapy for the purposeof participating in this research study

No

241Provide a justification for discontinuing subjects from known effective therapy for the



purpose of study participation

242Describe the risks to subjects associated with discontinuing them from known effectivetherapy for the purpose of study participation

View 205


25 Will screening procedures (ie procedures to determine research subject eligibility) beperformed specifically for the purpose of this research study

No

251List the screening procedures that will be performed for the purpose of this researchstudy Do NOT include the inclusionexclusion criteria in this section as they will beaddressed in section 3 questions 313 and 314

252What steps will be taken in the event that a clinically significant unexpected disease orcondition is identified during the conduct of the screening procedures

Addressed below

Participants will be under the clinical care of a member of the Department of OtolaryngologyAny disease or condition identified during the course of this research will be addressedfollowing standard clinical procedure

View 206


26 Provide a detailed description of all research activities (eg all drugs or devicespsychosocial interventions or measures) that will be performed for the purpose of thisresearch study

This description of activities should be complete and of sufficient detail to permitan assessment of associated risks

At a minimum the description should include



all research activitiespersonnel (by role) performing the procedureslocation of proceduresduration of procedurestimeline of study procedures

Individuals seen by Department of Otolaryngology physiciansclinicians having developedtreatment associated dysphagia after completing non-operative treatment with chemoradiationor radiation therapy alone for oral oropharyngeal hypopharyngeal or laryngeal cancer willbe approached for participation during the course of usual clinical care in the Dept of ENTclinical offices designated in this protocol

Once enrolled through written informed consent research participants will be assigned toeither standard therapy or to standard therapy with IOPI treatment group by a clinicalinvestigator This assignment will be in an alternating fashion based on date of enrollmentIOPI treatment consists of 10 repetitions of the IOPI exercises three times a day on three daysper week for 8 weeks It will take 30 minutes to train the subject on how to do the exercisesand record them and that it takes 5-10 minutes to complete 30 repetitions of the exerciseSubjects will be completing a diary related to their exercise regimen

Subjects will undergo a standard of care modified barium swallow study by clinical staff priorto the onset of therapy to obtain baseline measurements of airway protection andoropharyngeal kinematic function They will also be asked to complete a Visual Analog Scale(VAS) to rate their dysphagia prior to initiation of therapy therapy by marking an ldquoXrdquo on a100mm line indicating their perception of the severity of their dysphagia (0 = least severe100 = most severe) They will also be asked to complete a dietary assessmenttoolquestionnaire consisting of 10 items (EAT-10) Tongue isometric pressure generation(strength) will be measured with the IOPI This requires the subject to press a small plasticair-filled bulb between the tongue and hard palate which transfers isometric pressure on theIOPI The Functional Oral Intake Scale (FOIS) will be used by the clinician to rate currentlevel of oral intake Finally subjects will be weighed

Approximately 8 weeks after the initiation of therapy (standard or standard w IOPI)individuals will be asked to complete the VAS and the EAT-10 and the clinician will repeatthe FOIS and weigh the subjects once again at their 8-week standard of care clinical followup visit 8 weeks is the usual standard of care follow up visit A modified barium swallow(MBS) test will also be performed as part of standard of care at about the 8 week time point(after therapy) Finally isometric pressure (tongue strength) will be measured at this point

At 8 weeks individuals who were assigned to the standard therapy only group who stillrequire swallowing therapy will be asked if they would like to add the IOPI to their therapy



program (crossover) If they agree they will be trained to use the IOPI and use it togetherwith their standard therapy program for an additional 8 weeks Lingual strength with theIOPI weight FOIS VAS and EAT-10 will be collected both before and after the initiation ofthis addition to their therapy A standard of care MBS will again be performed after 8 weeksof therapy with IOPI in this group Those who still require swallowing therapy and do notwish to add the IOPI to their standard of care therapy program will continue in their standardtherapy program

Individuals (in either group) who do not require additional swallowing therapy at the end ofstudy participation will discontinue their standard of care therapy program altogether

261Will blood samples be obtained as part of this research study

No

If submitting a protocol for expedited review it should be clear that the planned blood drawsare within the parameters described here httpwwwhhsgovohrppolicyexpedited98html (see Expedited Research Category 2)

If Yes address the frequency volume per withdrawal the total volume per visit and thequalifications of the individual performing the procedure

The purpose of the flowchart is to enhance and not replace the detailed description for allresearch activities in question 26

It is the responsibility of the PI to ensure consistency of the content within the entire IRBapplication which includes all uploaded documents (eg sponsor protocol consent flowcharts)

Study Flow ChartName Modified DateFlow Chart 912015 1010 AM

View 207 - 207(b)




27Will follow-up procedures be performed specifically for research purposes Follow-upprocedures may include phone calls interviews biomedical tests or other monitoringprocedures

Yes

Detailed procedures listed in the textbox below

The follow up procedures outlined in 26 The modified barium swallow FOIS and patientweight are routinely performed with clinical patients Among the procedures in this study theonly ones used for research purposes are the visual analog scale the EAT-10 and themeasurement of tongue strength with the IOPI

Approximately 8 weeks after the initiation of therapy (standard or standard w IOPI)individuals will be asked to complete the VAS and the EAT-10 and the clinician will repeat theFOIS and weight the subjects once again at their 8-week standard of care clinical follow upvisit 8 weeks is the usual standard of care follow up visit A modified barium swallow (MBS)test will also be performed as part of standard of care at about the 8 week time point Finallyisometric pressure (tongue strength) will be measured at this point

View 208


28Does this research study involve the use of any questionnaires interview or surveyinstruments

Yes

Upload a copy of all materials except for the SCID or KSADS which are on file at theIRB The use of all instruments must be addressed in question 26 andor question 27(except for an exempt submission where they should be addressed on the appropriateuploaded exempt form)

Name Modified DateFOIS scale 912015 915 AMEAT-10docx 8272015 425 PMVAS-dysphagia IOPIdocx 8272015 428 PM

Previously the name and publisher for commercially available materials were listed in thetextbox below but effective 912015 all materials (except for the SCID and KSADS) must



be uploaded using the Add button aboveBelafsky PC Mouadeb DA Rees CJ Pryor JC Postma GN Allen J Leonard RJ Validity andReliability of the Eating Assessment Tool (EAT-10) Annals of OtologyRhinology amp Laryngology 2008117(12)919-924

View 209 - 210


29 If subjects are also patients will any clinical procedures that are being used for theirconventional medical care also be used for research purposes

yes

If Yes describe the clinical procedures (and if applicable their frequency) that will beused for research purposes Information contained in their electronic medical record related to their qualifying diagnosisand swallowing difficulty will be accessed for this research Specifically MBS evaluationswill be accessedreviewed as part of the assessment process for the specific aims of thisresearch

210 The blood sample question was moved to 261

View 211


211What is the total duration of the subjects participation in this research study across allvisits including follow-up surveillance

Approximately 8 weeks for IOPI plus standard therapy Approximately 16 weeks for thecrossover group

View 212


212 Does this research study involve any type of planned deception If Yes you are required to request an alteration of the informed consent process (question47)

No

2121Describe the planned deception



2122Provide a justification for this planned deception

2123Describe when and how subjects will be debriefed

View 213 HB


213 Does this research study involve the use of UPMCPitt protected health informationthat will be de-identified by an IRB approved honest broker system

No

2131Identify the name of the honest broker system

2132Specify the IRB-assigned honest broker system number (eg HB123456)

2133Specify the names of the individuals who will provide the honest broker services

Last First OrganizationThere are no items to display

Previous inputted information for Question 2133

2134Upload the signed honest broker assurance agreement

Name Modified DateThere are no items to display

View 214


214 Will protected health information from a UPMCPitt HIPAA covered entity beaccessed for research purposes or will research data be placed in the UPMCPittmedical record



Yes

If you answer Yes you are required to submit this study to the Center for Assistance inResearch using e-Record (CARe) Per UPMC Policy HS-RS0005 all research projects thataccess or involve UPMC electronic protected health information (e-PHI) must be submittedto CARe with the exception of clinical trials that are contracted through the UPMC Officeof Sponsored Programs and Research Support (OSPARS)

Complete the online submission form at httpscareupmccomrequestaspx After the studyis submitted in OSIRIS a CARe representative will conduct a review You will be notifiedonce your CARe review is complete or if anything further is needed

Studies that will access only paper-based medical records (not in combination with anyelectronic records) do not need to be submitted to CARe

For additional information please see hpscareupmccom

Describe the medical record information that will be collected from the UPMCPittHIPAA covered entity andor the research-derived information that will be placed inthe medical records

Information to be collected1 site and staging of qualifying headneck cancer2 modified barium swallow video data 3 medical history of pneumonia feeding tubes4 patient age and gender date of completion or cancer treatment type of chemotherapy andtotal radiation therapy dosage

Research information to be placed into medical records would include1 Outcomes of therapy (including IOPI resultstongue strength)2 Changes of research outcome measures pertinent to patient clinical care3 Type of exercise regimen the participant used

2141Will protected health information from a non-UPMCPitt HIPAA covered entity beobtained for research purposes or will research data be placed in the non-UPMCPittmedical record

No



If Yes describe how the HIPAA requirements will be met

I Jonas Johnson certify that any member of my research team accessing reviewingandor recording information from medical records have completed the CITI Privacyamp Information Security course or if completed within the past year the Internet-BasedStudies in Education and Research (ISER) HIPAA for Researchers (Formerly RPFModule 6) The HIPAA certificates must be available for review if audited but do notneed to be uploaded into this OSIRIS application

Yes

2142Are you requesting a waiver of the requirement to obtain written HIPAA authorizationfor the collection of the PHI

No

View 215


215 Does this research study involve the long-term storage (banking) of biologicalspecimens

No

2151Broadly describe the intended future use of the banked biological specimens

2152Indicate the planned length of storage of the banked biological specimens

2153Will biological specimens be stored without identifiers or linkage codes

If you answer Yes the samples will not be stored with any identifiers or linkage codesand it is highly unlikely to be linked back to the individual

If you answer No the samples will be stored with an identifier or linkage code and canbe linked back to the individual



View 216


216 Will research participants be asked to provide information about their family membersor acquaintances

No

2161Describe what information about the third party will be obtained from the participant

2162If the information about the third party is of a private nature can the identity of thethird party be readily ascertained or associated with this information

Describe the private information that will be collected and recorded about the third party

View 217 - 218


217What are the main outcome variables that will be evaluated in this study

1 Tongue pressure generation (strength) 2 Airway protection during swallowing (penetration-aspiration scale score of MBS data) 3 Pharyngeal residue after swallowing (pharyngeal retention scale rating of MBS data) 4 Swallowing impairment based on EAT-10 VAS FOIS 5 Swallow kinematic measures of MBS data on a swallow by swallow basis(videofluoroscopic image analysis with image processing software)a oral transit duration (duration of bolus transit through the oral cavity)b stage transition duration (measure of pharyngeal onset delay time)c duration of impaired oral containment (measure of bolus control in the oral cavity)d pharyngeal transit duration (duration of bolus transit from oral cavity to inferior pharynx)e pharyngeal response duration (duration of hyoid bone maximal movement during theswallow)f duration of upper esophageal sphincter openingg laryngeal closure duration (duration of airway closure)h we may analyze the magnitude of epiglottic inversion (rotation of the epiglottis duringswallows which relates to laryngeal closure)



i we may analyze the magnitude of hyoid displacement (distance traveled by the hyoid bondduring swallows)

218Describe the statistical approaches that will be used to analyze the study data

Addressed below

We will perform t-tests to compare the dependent variable values from each measure(penetration-aspiration scores pharyngeal retention scores swallow kinematic measurestongue pressure scores EAT-10 scores VAS scores and patient weight We may also performANOVAs and post hoc analyses to determine the main effect of treatment condition on thedependent variables and to determine the presence of any interaction effects and singlesubject analyses using the C statistic to detmine individual effect sizes for individualparticipants Analyses will be designed to compare performance at the following time points

1 between groups comparisons at time 1 (start of treatment) and at 2 (end of treatment) toevaluate differences between groups at the start and end of 8 weeks of therapy

2 within groups comparisons between time 1 and 2 (standard therapy vs standard therapy +IOPI) to evaluate the magnitude of differences from beginning to end of therapy

3 within group comparison (standard treatment crossover only) at time 1 and time 3 (8 weeksafter crossover of standard treatment subjects into standard therapy + IOPI) to evaluate themagnitude of differences from beginning of therapy to end of second phase of therapy(combined standard therapy with crossover to standard + IOPI)

View 219 - 2196


219 Will this research be conducted in (a) a foreign country andor (b) at a site (egNavajo Nation) where the cultural background of the subject population differssubstantially from that of Pittsburgh and its surrounding communities

No

Note that copies of training records licenses certificates should be maintained in thestudy regulatory binder and are subject to audit by the Research Conduct andCompliance Office (RCCO)



In addition individuals planning to conduct human subject research outside the UnitedStates must complete an optional module on the CITI training website InternationalStudies Click here to access the instruction sheet for accessing optional CITI modules

2191 Address the following for each of the foreignculturally different sites where thisresearch will be conducted

bull Name of sitebull Name of authorized individual (eg IRB Chair) from the local IRB or other humansubject protections entity that is responsible for the review and approval of the projectupload approval letter with an English translation if applicable bull Name and qualifications of the site collaborator responsible for the conduct of theresearch (eg site PI)bull The anticipated number of subjects that will be enrolled at that site bull If Federally funded provide the Federalwide Assurance number (FWA) assigned to thesite

Site Date ModifiedThere are no items to display

21911Provide a description of the context of cultural norms and local laws and highlightdifferences between US culture in all areas relevant to your study including at aminimum

bull Age of majority of participants to be enrolledbull If study includes minors or decisionally impaired subjects summarize laws onguardianship bull If your study involves any invasive medical procedure (including blood draws) provideassurance that the individuals undertaking those procedures for research purposes areappropriately credentialed bull If your study involves the administration of a drug device or biologic for researchpurposes describe the process for shipping labeling storing and dispensing and indicatehow these are consistent with all relevant local (and US) laws including those requiringimport export permitsbull If your study involves collection of biological specimens describe the process forshipping labeling storing and using such samples Identify any special local consentrequirements and any special permits that may be required by local law



2195 If the researcher is a student describe how the student will communicate with theadvisor during the conduct of the research and how the advisor will oversee theresearch

View 221


221 Will this research study be conducted within a nursing home located in Pennsylvania

No

2211Does this research involve a medical procedure or an experimental treatment

2212Does the research study involve the exposure of nursing home residents to pain injuryinvasion of privacy or ask the resident to surrender autonomy

If Yes to either question upload the Pennsylvania Department of Health approval letter 28 PA Code Section 20129 (o) specifies that prior to the initiation of research and inaddition to IRB approval any study that includes experimental research or treatmentconducted in a nursing home must be approved by the Pennsylvania Department of HealthA signed consent form from nursing home resident-subject is also required

NameModified Date

View 301 - 304(a)

Section 3 - Human Subjects

31 What is the age range of the subject population

18 and older



32 What is their gender

Both males and females

Provide a justification if single gender selected

33 Will any racial or ethnic subgroups be explicitly excluded from participation

No

If Yes identify subgroups and provide a justification

34 For studies conducted in the US do you expect that all subjects will be able tocomprehend English

Yes

If No identify what languages will be understood by subjects and describe your plan tomanage communication with non-English speaking subjects during all phases of the study

341If translated documents are used upload a signed translator certification form and backtranslations (if applicable)


View 305 - 305(a)


35 Participation of Children Will children less than 18 years of age be studied

No

If No provide a justification for excluding children The number of children under the age of 18 with the qualifying diagnosis is minimal Theamount of information to be obtained from this small population is minimal

351 Specify the age range of the children to be studied (Check all that apply below)



ChoicesThere are no items to display

352 Provide a rationale for the specific age ranges of the children to be studied

353 Describe the expertise of the study team for conducting research with children withinthis age range

3531Have you obtained the following clearances from all research staff who may havedirect contact with children under the age of 18 Direct contact under the lawincludes face-to-face and telephonic or electronic contact with minors Please see theChild Clearances guidance document for further explanation

Pennsylvania Department of Public Welfare Child Abuse History ClearancePennsylvania State Police Criminal Record Check andFBI Criminal Background Check

Note If No once all clearances are obtained a modification must be submitted

If you selected NA please explain

It is important to note that ldquodirect contactrdquo refers not only to face-to-face meetings butalso extends to communication via phone (including text messaging) social media orinternet Direct contact also includes the care guidance supervision or control orroutine interaction with minors Conversely a participating investigator or support staffmember who does not have direct contact either electronically or in person withchildren does not need to obtain clearances (eg statistician non-clinical laboratorypersonnel etc) If your research study provides babysitting services the babysittersmust have the required child clearances

Note It is the responsibility of the principal investigator to ensure that all researchstaff have these clearances prior to any interaction with children Contact HumanResources at 412-624-8150 for assistance with this process



354 Describe the adequacy of the research facilities to accommodate children within thisage range

355 Permitted Categories of Research The Federal Policy and FDA regulations governinghuman subject protections specify that research involving children must fall into oneof the following permitted categories

45 CFR 46406

The risk represents only a minor increase over minimal riskThe research procedures present experiences to the subjects that are reasonablycommensurate with those inherent in their actual or expected medical dentalpsychological social or educational situationsThe research procedures are likely to yield generalizable knowledge about thesubjectsrsquo disorder or condition which is of vital importance for understanding oramelioration of the subjectsrsquo disorder or condition

45 CFR 46407

The risk is justified by the anticipated benefit to the subjects and the relation of theanticipated benefit to the risk is at least as favorable to the subjects as that presentedby available alternative approaches

Provide a justification which must address all considerations related to thedesignated category of research

View 306


36 Does this research study involve prisoners or is it anticipated that the research studymay involve prisoners

No

361The Federal Policy and FDA regulations specify that research involving prisoners mustfall into one of the following permitted categories



Provide a justification for your designation

General Requirements The Federal Policy and FDA regulations specify that researchinvolving prisoners must also conform to each of the following general requirements Describe how your study meets each of the following regulations

362Any possible advantages accruing to the prisoner through his or her participation in theresearch when compared to the general living conditions medical care quality of foodamenities and opportunity for earnings in the prison are not of such a magnitude thatthe prisonerrsquos ability to weigh the risks of the research against the value of suchadvantages in the limited choice environment of the prison is impaired [45 CFR 46305(a)(2)]

363The risks involved in the research are commensurate with risks that would be acceptedby nonprisoner volunteers[45 CFR 46305 (a)(3)]

364The procedures for the selection of subjects within the prison are fair to all prisonersand immune from arbitrary intervention by prison authorities or prisoners[45 CFR 46305 (a)(4)]

365Information regarding the research is presented to the potential prisoners-subjects in alanguage which is understandable to them[45 CFR 46305 (a)(5)]

366Adequate assurance exists that the parole boards will not take into account a prisonerrsquosparticipation in the research in making decisions regarding parole and each prisoner isclearly informed in advance that participation in the research will have no effect on his

or her parole [45 CFR 46305 (a)(6)]

367Where there may be a need for follow-up examination or care of the prisoners-subjectsafter the end of their participation in the research adequate provision has been madefor such examination or care taking into account the varying lengths of individualprisonersrsquo sentences and the prisoners have been informed of this fact [45 CFR 46305(a)(7)]



View 307


37 Will pregnant women be knowingly and purposely included in this research study

No

General Requirements The Federal Policy [45 CFR 46 Subpart B] specify that researchinvolving pregnant women andor fetuses must also confirm to each of the following criteriaDescribe how your study meets each of the requirements

371Where scientifically appropriate preclinical studies including studies on pregnantanimals and clinical studies including studies on non-pregnant women have beenconducted and provide data for assessing potential risks to pregnant women and fetuses[45 CFR 46204 (a)] [Include references]

372The risk to the fetus is caused solely by interventions or procedures that hold out theprospect of direct benefit for the women or the fetus or if there is no such prospect ofdirect benefit the risk to the fetus is not greater than minimal and the purpose of theresearch is the development of important biomedical knowledge which cannot beobtained by any other means [45 CFR 46204 (b)]

373Any risk is the least possible for achieving the objectives of the research [45 CFR 46204(c)]

374No inducements monetary or otherwise will be offered to terminate the pregnancy [45CFR 46204 (h)]

375Individuals engaged in the research will have no part in any decisions as to the timingmethod or procedures used to terminate a pregnancy [45 CFR 46204 (i)]



376Individuals engaged in the research will have no part in determining the viability of a

neonate [45 CFR 46204 (j)]

View 308


38 Does this research study involve neonates of uncertain viability or nonviable neonates

No

General Requirements The Federal regulations [45 CFR 46205] specify that researchinvolving neonates of uncertain viability and nonviable neonates must conform to each ofthe general requirements Describe how each of the following requirements will be met

381 Where scientifically appropriate preclinical and clinical studies have been conductedand provide data for assessing potential risks to neonates (include references) [45 CFR46205 (a)(1)]

382 Individuals engaged in the research will have no part in determining the viability ofthe neonate [45 CFR 46205 (a)(3)]

383 Does this research study involve neonates of uncertain viability [45 CFR 46205(b)]

3831The Federal regulations specify that until it is ascertained whether or not a neonate isviable a neonate may not be involved in research unless one of the followingconditions is met

Provide a justification for your selection

384 Does this research study involve nonviable neonates [45 CFR 46205(c)]



General Requirements The Federal regulations specify that after delivery a nonviableneonate may not be involved in research unless each of the following additional conditionsare met [45 CFR 46205(c)]

3841Vital functions of the neonate will not be artificially maintained [45 CFR 46205 (c)(1)]

3842The research will not terminate the heartbeat or respiration of the neonate [45 CFR46205 (c)(2)]

3843There will be no added risks to the neonate resulting from the research [45 CFR46205 (c)(3)]

3844The purpose of the research is the development of important biomedical knowledgethat cannot be obtained by other means [45 CFR 46205 (c)(4)]

View 309


39 Fetal Tissues Does this research involve the use of fetal tissues or organs

No

General Requirements In accordance with the Pennsylvania Abortion Control Act fetaltissues or organs may only be obtained for use in research subsequent to obtaining the writteninformed consent of the mother The Pennsylvania Abortion Control Act specifies thatresearch involving the use of fetal tissue or organs must also conform to each of thefollowing requirements [Indicate how you will conform to each requirement]



391Informed consent for the research use of fetal tissue derived from an abortion will beobtained separate from and after the decision and consent to abort has been made

392No consideration of any kind (ie monetary or otherwise) will be offered to the motherin obtaining her consent for the research use of the fetal tissue or organs

393The mother will not be permitted to designate a recipient of the fetal tissue or organs foruse in research

394All persons who participate in the procurement or use of the fetal tissue or organs willbe informed as to the source of the tissue (eg abortion miscarriage stillbirth ectopicpregnancy)

View 310 - 312(a)---gt


310What is the total number of subjects to be studied at this site including subjects to bescreened for eligibility

Note The number below is calculated by summing the data entered in question 311 Anyadditions or changes to the values entered in 311 will be reflected in 310

100

311Identify each of the disease or condition specific subgroups (include healthy volunteers ifapplicable) that will be studied

Click on the Add button and specify for each subgroup

1) how many subjects will undergo research related procedures at this site and

2) if applicable how many subjects will be required to undergo screening procedures(eg blood work EKG x-rays etc) to establish eligibility Do Not include subjects who



will undergo preliminary telephone screening

SubgroupNumber to undergo researchprocedures

Number to undergo screeningprocedures

ViewStandard Therapyplus IOPI

50 0

ViewStandard Therapy 50 0

312Provide a statistical justification for the total number of subjects to be enrolled into thisresearch study at the multicenter sites or this site

Described below This is a pilot study Enrollment numbers were determined through a review of the referralbase and realistic expectations for recruitment

View 313 - 315(a)


313Inclusion Criteria List the specific criteria for inclusion of potential subjects

Age 18 and olderDiagnosed with oral oropharyngeal hypopharyngeal or laryngeal cancer having non-surgicaltreatment with chemoradiation or radiation therapy alone resulting in treatment associateddysphagia

314Exclusion Criteria List the specific criteria for exclusion of potential subjects fromparticipation

1 Unable to adhere to assigned therapy program due to cognitive deficits 2 Surgical treatment for head and neck cancer 3 unable to give informed consent 4 Past or current history of temperomandibular joint dysfunction5 Past or current history of myofacial pain disorders



315Will HIV serostatus be evaluated specifically for the purpose of participation in thisresearch study

No

If Yes provide a justification

View 401 - Version 2

Section 4 - Subject Recruitment and Informed Consent Procedures

41Select all recruitment methods to be used to identify potential subjectsOther Strategies Described below

Advertisements

Upload the advertisements for reviewNameModified Date

Honest Broker

Identify the name of the honest broker system and name of the specific individuals who willprovide those services

Specify the IRB-assigned honest broker system number (eg HB123456)

Upload the signed honest broker assurance agreementName Modified DateThere are no items to display

Recruitment Letters and Scripts

Upload recruitment lettersscriptstextNameModified Date



Research Registry

List the IRB approval number and title for each registry source

42Provide a detailed description of your recruitment methods including identifying andinitiating contact with participants

Potential research subjects will be initially contacted at the University of Pittsburgh MedicalCenter Department of Otolaryngology outpatient clinic while there for routine clinicalevaluation They will be approached by their clinician who may also be an investigator of thisresearch project The investigator or clinician who will be trained in all research procedureswill present information about this research study If the potential research subject is interestedthe informed consent process will be initiated

Note Questions jump from 42 to 46 as questions 43-45 have been removed and the information isnow captured in 41View 406


46 Are you requesting a waiver to document informed consent for any or all participantsfor any or all procedures (eg a verbal or computerized consent script will be usedbut the subjects will not be required to sign a written informed consent document This is not a waiver to obtain consent

No

461 Identify the specific research procedures andor the specific subject populations forwhich you are requesting a waiver of the requirement to obtain a signed consent form

If not all identify the specific procedures andor subject populations for which you arerequesting a waiver

462 Indicate which of the following regulatory criteria is applicable to your request for awaiver of the requirement to obtain a signed consent form



45 CFR 46117(c)(1) That the only record linking the subject and the research would be the consent document and theprincipal risk would be potential harm resulting from a breach of confidentiality Each subject will be asked whether thesubject wants documentation linking the subject with the research and the subjects wishes will govern or

45 CFR 46117(c)(2) That the research presents no more than minimal risk of harm to subjects and involves noprocedures for which written consent is normally required outside of the research context

4621Address why the specific research procedures for which you are requesting a waiver ofthe requirement to obtain a signed consent form present no more than minimal risk ofharm to the research subjects

4622Justify why the research listed in 461 involves no procedures for which writteninformed consent is normally required outside of the research context

463 Address the procedures that will be used and the information that will be provided(ie script) in obtaining and documenting the subjects verbal informed consent forstudy participation

Upload ScriptsNameModified Date



47 Are you requesting a waiver to obtain informed consent or an alteration of the informedconsent process for any of the following

No

471If Yes select the reason(s) for your requestThere are no items to display

General Requirements The Federal Policy [45 CFR 46116 (d)] specifies in order for awaiver of consent to be approved the request must meet four criteria For each request youwill be asked to provide a justification addressing how each of these criterion is met

Medical record review for the identification of potential subjects



The research involves no more than minimal risk to the subjects [45 CFR 46116 (d)(1)]

The waiver or alteration will not adversely affect the rights and welfare of the subjects[45 CFR 46116 (d)(2)]

The research could not practicably be carried out without the waiver or alteration[45 CFR 46116 (d)(3)]

Whenever appropriate the subjects will be provided with additional pertinent informationafter participation [45 CFR 46116 (d)(4)]

Review of identifiable medical records [Note A waiver of HIPAA Authorization must berequested (2142)] Include the approximate number of medical records andorspecimens that will be accessed and enter -1 in question 311 for the number of subjectsto be enrolled

The research involves no more than minimal risk to the subjects[45 CFR 46116 (d)(1)]



Whenever appropriate the subjects will be provided with additional pertinent informationafter participation[45 CFR 46116 (d)(4)]

Parental Permission andor Child Assent




Whenever appropriate the subjects will be provided with additional pertinent information



after participation[45 CFR 46116 (d)(4)]

Alteration of informed consent process




aWhenever appropriate the subjects will be provided with additional pertinent informationafter participation[45 CFR 46116 (d)(4)]

Other Minimal Risk activity





472Under what circumstances (if any) will you obtain consent from some of these subjects

View 408




48Are you requesting an exception to the requirement to obtain informed consent forresearch involving the evaluation of an emergency procedure

Note This exception allows research on life-threatening conditions for which availabletreatments are unproven or unsatisfactory and where it is not possible to obtain informedconsent

No

View 409 Informed Consent


49 Upload all consent documents for watermarking

Draft Consent Forms for editingName Modified DateUPMC ICF - IOPI RTC2doc10212015 416 PM

Approved Consent Form(s)Name Modified DateUPMC ICF - IOPI RTC2doc7252017 1032 AM

View 410


410 Will all potential adult subjects be capable of providing direct consent for studyparticipation

Yes

Indicate why direct consent is not possible

4101Provide a justification for the inclusion of adult subjects who are unable to providedirect consent for study participation



4102Specify the criteria used to determine that a potential adult subject is not able toprovide direct consent for participation and identify who will be responsible for thatdetermination

4103Will you obtain the potential adult subjects assent for study participation

If No provide a justification for not obtaining assent

4104Identify who will provide proxy consent for the participation of the decisionallyimpaired adult

View 411 - 411(b)


411 At what point will you obtain the informed consent of potential research subjects ortheir authorized representative

Prior to performing any of the research interventionsinteractions

If Other address below

4111Address why you feel that it is acceptable to defer obtaining written informed consentuntil after the screening procedures have been performed

4112Taking into account the nature of the study and subject population indicate how theresearch team will ensure that subjects have sufficient time to decide whether toparticipate in this study In addition describe the steps that will be taken to minimizethe possibility of coercion or undue influence

Patients will be provided with the information about the study They will be told it is theirchoice if they wish to participate and that it will not affect the care they receive Clinicalcare will continue as directed regardless of participation in this research

View 412 - 414(a)




412Describe the process that you will employ to ensure the subjects are fully informedabout this research study

Addressed below This description must include the following elements

who from the research team will be involved in the consent process (both the discussionand documentation)person who will provide consent or permission information communicated andany waiting period between informing the prospective participant about the study andobtaining consent

In addition address the following if applicable based on your subject population

process for child assent and parental permissioncontinued participation if a child subject turns 18 during participation

process for obtaining proxy consent and assent for decisionally impaired subjectscontinued participation if subject regains capacity to consent

The potential research subject will be approached by their clinician who may also be aninvestigator on this research study The clinician or investigator will provide information aboutparticipation including the purpose of the study the potential risks and benefits of studyparticipation and their rights as a research subject The clinician or the investigator will gothrough the informed consent document with the potential research subject prior to enrollmentThe investigator andor clinician will answer any questions that the potential research subjectmay have about this research study Consent will ultimately be obtained by the clinician or oneof the investigators on this project as approved by the IRB

413Are you requesting an exception to either IRB policy related to the informed consentprocess

For studies involving a drug device or surgical procedures a listed physicianinvestigator is required to obtain the written informed consent unless an exception tothis policy has been approved by the IRB For all other studies a listed investigator is required to obtain consent (Note In order torequest an exception to this policy the study must be minimal risk)

Yes



If Yes provide a justification and describe the qualifications of the individual who will obtainconsentWe are requesting an exception to the IRB policy requiring a listed physician investigator toobtain written informed consent from participantsThe reason for this request is that additional clinicians in the Department of Otolaryngologywill have the required knowledge to complete the informed consent process Currently thereare 5 Speech Language Pathologists (currently not listed as co-investigators) that will bedirectly involved in the care of the participants These individuals will be assisting with theswallowing testing as well as instructing the subjects in the proper therapy techniques andproper use of the IOPI device With proper instruction on the details of the protocol theseadditional 5 SLPs who are assisting directly with the care of these individuals will beadequately qualified to answer questions related to this research

414Will you inform research subjects about the outcome of this research study following itscompletion

No If Yes describe the process to inform subjects of the results

View 5011 - 5012 Version 2

Section 5 - Potential Risks and Benefits of Study Participation

51 Describe potential risks (physical psychological social legal economic orother) associated with screening procedures research interventionsinteractions andfollow-upmonitoring procedures performed specifically for this study

View

ResearchActivity

medical record reviewdata collection

CommonRisks

No Value Entered

InfrequentRisks

Rare risk of confidentiality breach

Other Risks No Value Entered



View

ResearchActivity

Questionnaires

CommonRisks

No Value Entered

InfrequentRisks

possible emotional distress


View

ResearchActivity

tongue exercises

CommonRisks

soreness of tongue or jaw muscles

InfrequentRisks

No Value Entered


511Describe the steps that will be taken to prevent or to minimize the severity of thepotential risks

Experienced personnel and staff will be conducting all proceduresResearch data being collected for this study may be in either electronic or paper form Allelectronic data will be stored on restricted access password protected servers Any paper datawill be stored in locked cabinets within the offices of the Department of OtolaryngologyIndividuals reviewing this data will have completed the appropriate training regardingconfidentiality Only individuals directly involved with the conduct of this research will bepermitted access to the data

It will be necessary to collect personal identifiable information as subjects will be followedover a several month time period depending on their clinical treatment Medical recordinformation will be accessed during participation so personal identifiable information willneed to be captured Muscle soreness will managed by decreasing the target pressure of the IOPI device for thesubject This device must be kept out of the reach of children While the instructions of thedevice state that a medical professional should hold onto tube all subjects will beinstructed on the safeappropriate method of using the device This may include a familymember assisting in the use of the device or the subject holding on to the tube on their ownThis process will be discussed in depth during the instruction period prior to the start of IOPItherapy Any participant with poor comprehension of these instructions (in the opinion of aresearch team member) may be removed from the study for safety reasons



Subjects will be instructed to skip any questions that they are not comfortable answering

52 What steps will be taken in the event that a clinically significant unexpected disease orcondition is identified during the conduct of the study

Addressed below


53 All the risk questions (screening interventioninteraction follow-up) have been merged intoone question (51)

View 504


54 Do any of the research procedures pose a physical or clinically significant psychologicalrisk to women who are or may be pregnant or to a fetus

No

541List the research procedures that pose a risk to pregnant women or fetuses

542Describe the steps that will be taken to rule out pregnancy prior to exposing women ofchild-bearing potential to the research procedures that pose a risk to pregnant womenor fetuses

543Describe the measures to prevent pregnancy and their required duration of use thatwill be discussed with women of child-bearing potential during and following exposureto research procedures

View 505


55 Do any of the research procedures pose a potential risk of causing genetic mutations thatcould lead to birth defects

No

551List the research procedures that pose a potential risk of genetic mutationsbirth



defects

552Describe the measures to prevent pregnancy and their required duration ofuse in female subjects and female partners of male subjects during and followingexposure to research procedures

View 506 - 506(a)


56Are there any alternative procedures or courses of treatment which may be of benefit tothe subject if they choose not to participate in this study

Yes - Describe below

If Yes describe in detailYes Standard swallowing therapy for individuals with treatment associated dysphagia

View 507 - 507(a)


57Describe the specific endpoints (eg adverse reactionsevents failure to demonstrateeffectiveness disease progression) or other circumstances (eg subjects failure to followstudy procedures) that will result in discontinuing a subjectrsquos participation

Describe below

It may be possible that subjects may be removed for the following reasonIf subject is unable to cognitively understand the exercises

Information related to non-compliance is important to be noted Subjects who are non-compliant will not be removed

View 508 -508(a)


58 Will any individuals other than the investigatorsresearch staff involved in the conductof this research study and authorized representatives of the University Research



Conduct and Compliance Office (RCCO) be permitted access to researchdatadocuments (including medical record information) associated with the conduct ofthis research study

Yes

581Identify the external persons or entity who may have access to researchdatadocuments and the purpose of this access

Although we do not currently plan on sharing data should we decide to share data in thefuture we will contact the Office of Research to determine whether an agreement needs to beexecuted

582Will these external persons or entity have access to identifiable researchdatadocuments

No the research datadocuments will be coded and subject identifiers removed prior to accessby the external persons

If Yes describe how they will protect the confidentiality of the research data

59 Has or will a Federal Certificate of Confidentiality be obtained for this research study

No

510 Question has been moved to 517


View 512 - 513


512Does participation in this research study offer the potential for direct benefit to theresearch subjects

Yes - Describe the direct benefit that subjects may receive as a result of study participationIndicate if all or only certain of the subjects may derive this potential benefit Describe the benefitIt is possible that individuals assigned to the group using IOPI may experience an accelerated



rate of recovery related to their dysphagia They may also experience an enhanced recovery

513Describe the data and safety monitoring plan associated with this study If the researchstudy involves multiple sites the plan must address both a local and central reviewprocess

The investigators and research staff will meet at least monthly to discuss the progress of theresearch study and to review all information related to this research study includingrecruitment confidentiality adverse events and patient safety The Principal Investigator DrJohnson will oversee these meetings A summary report will be provided to the IRB as part ofthe renewal process

View 514 - 517


514What precautions will be used to ensure subject privacy is respected (eg the researchintervention will be conducted in a private room the collection of sensitive information aboutsubjects is limited to the amount necessary to achieve the aims of the research so that nounneeded sensitive information is being collected drapes or other barriers will be used forsubjects who are required to disrobe)

All conversations with the patients will be conducted in closed door rooms as part of theirregular clinical appointment Information collected will be the minimum necessary tocontribute to the specific aims of this project

515What precautions will be used to maintain the confidentiality of identifiableinformation (eg paper-based records will be kept in a secure location and only beaccessible to personnel involved in the study computer-based files will only be made availableto personnel involved in the study through the use of access privileges and passwords prior toaccess to any study-related information personnel will be required to sign statements agreeingto protect the security and confidentiality of identifiable information whenever feasibleidentifiers will be removed from study-related information precautions are in place to ensurethe data is secure by using passwords and encryption because the research involves web-based surveys audio andor video recordings of subjects will be transcribed and thendestroyed to eliminate audible identification of subjects)

Paper based records will be kept in a secure location and only accessible to individualsdirectly involved in the study Electronic information will be stored on restricted accesspassword protected servers Subjects are assigned codes once enrolled but personal



identifiable information will be maintained to be able to access medical records as needed as itpertains to this research Documentation will contain identifiable information All electronicinformation will be maintained behind the UPMC firewall



Please select the external IRB of record

Provide the name of the Central IRB

Quality assurance projects are not subject to IRB review and approval UPMC has adopted anoversight process that requires the submission of all quality assurance projects for review AtUPMC submissions are reviewed by the Quality Improvement Review Committee (QRC)You can contact the QRC at askqrcupmcedu

Research studies that are limited to the inclusion of deceased individuals are not subject toIRB review and approval Research performed on individuals who have been declared legallydead andor research involving the collection of tissues from deceased individuals is notsubject prior review and approval by the University of Pittsburgh IRB

There are however ethical issues associated with research conducted on or involvingdeceased individuals To address these ethical issues all University faculty who desire toperform research on or involving deceased individuals must submit a project application forreview and approval by the Committee for Oversight of Research and Clinical TrainingInvolving the Dead Research Involving the Dead (CORID) Note that as per UPMC policiesresearch involving the medical records of deceased individuals is subject to obtaining thewritten consent of the decedentsrsquo next-of-kin or the executors of the decedentsrsquo estates

For studies that include BOTH living and deceased subjects IRB review and approval isrequired

Emergency Use is the use of a test article on a human subject in a life-threatening situation inwhich no standard acceptable treatment is available and in which there is not sufficient timeto obtain IRB approval [21 CFR312310] Detailed information on the submission process isavailable on the IRB website under the A-Z Guidance Emergency Use

All of the following conditions must exist to justify the emergency use of an unapprovedinvestigational drug biologic or device Check all the boxes that applySelectionsThere are no items to display



View T30

Triage Section


Minimal Risk




No


No

View CS010 - 0111

Cover Sheet Section




No





Previous IRB


No


View CS020 - 021

Cover Sheet Section













View CS030 - 039

Cover Sheet Section


Jonas Johnson

















412-647-2130


johnsonjtupmcedu

CS37 Fax Number

412-647-2080


No


No

View CS040

Cover Sheet Section





View CS050 - CS063

Cover Sheet Section




Christine Harrison




412-232-9097





View CS070

Cover Sheet Section


No





View CS080

Cover Sheet Section






View CS090 - 100

Cover Sheet Section


No



No








View CS110

Cover Sheet Section



NameModified Date



No

View CS120 - 140

Cover Sheet Section


No























No



Yes



Cover Sheet Section













Yes






View CS160

Cover Sheet Section


CategoriesNone

View CS170

Cover Sheet Section


No













View 201



No







View 202



Yes


No








Yes





No








No

View 204



No






View 205



No



Addressed below


View 206


















No






View 207 - 207(b)





Yes




View 208



Yes







View 209 - 210



yes



View 211




View 212



No






View 213 HB



No








View 214





Yes









No





Yes


No

View 215



No








View 216



No




View 217 - 218








Addressed below





View 219 - 2196



No













View 221



No




NameModified Date

View 301 - 304(a)



18 and older







No



Yes




View 305 - 305(a)



No


















45 CFR 46406


45 CFR 46407



View 306



No















View 307



No











View 308



No















View 309



No








View 310 - 312(a)---gt




100











50 0




View 313 - 315(a)









No





Advertisements


Honest Broker








Research Registry







No















No


































View 408






No






View 410



Yes









View 411 - 411(b)








View 412 - 414(a)













Yes









View

ResearchActivity


CommonRisks

No Value Entered

InfrequentRisks





View

ResearchActivity

Questionnaires

CommonRisks

No Value Entered

InfrequentRisks



View

ResearchActivity

tongue exercises

CommonRisks


InfrequentRisks

No Value Entered









Addressed below



View 504



No




View 505



No




defects


View 506 - 506(a)





View 507 - 507(a)



Describe below



View 508 -508(a)






Yes







No



View 512 - 513









View 514 - 517











View T30

Triage Section


Minimal Risk




No


No

View CS010 - 0111

Cover Sheet Section




No





Previous IRB


No


View CS020 - 021

Cover Sheet Section













View CS030 - 039

Cover Sheet Section


Jonas Johnson

















412-647-2130


johnsonjtupmcedu

CS37 Fax Number

412-647-2080


No


No

View CS040

Cover Sheet Section





View CS050 - CS063

Cover Sheet Section




Christine Harrison




412-232-9097





View CS070

Cover Sheet Section


No





View CS080

Cover Sheet Section






View CS090 - 100

Cover Sheet Section


No



No








View CS110

Cover Sheet Section



NameModified Date



No

View CS120 - 140

Cover Sheet Section


No























No



Yes



Cover Sheet Section













Yes






View CS160

Cover Sheet Section


CategoriesNone

View CS170

Cover Sheet Section


No













View 201



No







View 202



Yes


No








Yes





No








No

View 204



No






View 205



No



Addressed below


View 206


















No






View 207 - 207(b)





Yes




View 208



Yes







View 209 - 210



yes



View 211




View 212



No






View 213 HB



No








View 214





Yes









No





Yes


No

View 215



No








View 216



No




View 217 - 218








Addressed below





View 219 - 2196



No













View 221



No




NameModified Date

View 301 - 304(a)



18 and older







No



Yes




View 305 - 305(a)



No


















45 CFR 46406


45 CFR 46407



View 306



No















View 307



No











View 308



No















View 309



No








View 310 - 312(a)---gt




100











50 0




View 313 - 315(a)









No





Advertisements


Honest Broker








Research Registry







No















No


































View 408






No






View 410



Yes









View 411 - 411(b)








View 412 - 414(a)













Yes









View

ResearchActivity


CommonRisks

No Value Entered

InfrequentRisks





View

ResearchActivity

Questionnaires

CommonRisks

No Value Entered

InfrequentRisks



View

ResearchActivity

tongue exercises

CommonRisks


InfrequentRisks

No Value Entered









Addressed below



View 504



No




View 505



No




defects


View 506 - 506(a)





View 507 - 507(a)



Describe below



View 508 -508(a)






Yes







No



View 512 - 513









View 514 - 517












Previous IRB


No


View CS020 - 021

Cover Sheet Section













View CS030 - 039

Cover Sheet Section


Jonas Johnson

















412-647-2130


johnsonjtupmcedu

CS37 Fax Number

412-647-2080


No


No

View CS040

Cover Sheet Section





View CS050 - CS063

Cover Sheet Section




Christine Harrison




412-232-9097





View CS070

Cover Sheet Section


No





View CS080

Cover Sheet Section






View CS090 - 100

Cover Sheet Section


No



No








View CS110

Cover Sheet Section



NameModified Date



No

View CS120 - 140

Cover Sheet Section


No























No



Yes



Cover Sheet Section













Yes






View CS160

Cover Sheet Section


CategoriesNone

View CS170

Cover Sheet Section


No













View 201



No







View 202



Yes


No








Yes





No








No

View 204



No






View 205



No



Addressed below


View 206


















No






View 207 - 207(b)





Yes




View 208



Yes







View 209 - 210



yes



View 211




View 212



No






View 213 HB



No








View 214





Yes









No





Yes


No

View 215



No








View 216



No




View 217 - 218








Addressed below





View 219 - 2196



No













View 221



No




NameModified Date

View 301 - 304(a)



18 and older







No



Yes




View 305 - 305(a)



No


















45 CFR 46406


45 CFR 46407



View 306



No















View 307



No











View 308



No















View 309



No








View 310 - 312(a)---gt




100











50 0




View 313 - 315(a)









No





Advertisements


Honest Broker








Research Registry







No















No


































View 408






No






View 410



Yes









View 411 - 411(b)








View 412 - 414(a)













Yes









View

ResearchActivity


CommonRisks

No Value Entered

InfrequentRisks





View

ResearchActivity

Questionnaires

CommonRisks

No Value Entered

InfrequentRisks



View

ResearchActivity

tongue exercises

CommonRisks


InfrequentRisks

No Value Entered









Addressed below



View 504



No




View 505



No




defects


View 506 - 506(a)





View 507 - 507(a)



Describe below



View 508 -508(a)






Yes







No



View 512 - 513









View 514 - 517













View CS030 - 039

Cover Sheet Section


Jonas Johnson

















412-647-2130


johnsonjtupmcedu

CS37 Fax Number

412-647-2080


No


No

View CS040

Cover Sheet Section





View CS050 - CS063

Cover Sheet Section




Christine Harrison




412-232-9097





View CS070

Cover Sheet Section


No





View CS080

Cover Sheet Section






View CS090 - 100

Cover Sheet Section


No



No








View CS110

Cover Sheet Section



NameModified Date



No

View CS120 - 140

Cover Sheet Section


No























No



Yes



Cover Sheet Section













Yes






View CS160

Cover Sheet Section


CategoriesNone

View CS170

Cover Sheet Section


No













View 201



No







View 202



Yes


No








Yes





No








No

View 204



No






View 205



No



Addressed below


View 206


















No






View 207 - 207(b)





Yes




View 208



Yes







View 209 - 210



yes



View 211




View 212



No






View 213 HB



No








View 214





Yes









No





Yes


No

View 215



No








View 216



No




View 217 - 218








Addressed below





View 219 - 2196



No













View 221



No




NameModified Date

View 301 - 304(a)



18 and older







No



Yes




View 305 - 305(a)



No


















45 CFR 46406


45 CFR 46407



View 306



No















View 307



No











View 308



No















View 309



No








View 310 - 312(a)---gt




100











50 0




View 313 - 315(a)









No





Advertisements


Honest Broker








Research Registry







No















No


































View 408






No






View 410



Yes









View 411 - 411(b)








View 412 - 414(a)













Yes









View

ResearchActivity


CommonRisks

No Value Entered

InfrequentRisks





View

ResearchActivity

Questionnaires

CommonRisks

No Value Entered

InfrequentRisks



View

ResearchActivity

tongue exercises

CommonRisks


InfrequentRisks

No Value Entered









Addressed below



View 504



No




View 505



No




defects


View 506 - 506(a)





View 507 - 507(a)



Describe below



View 508 -508(a)






Yes







No



View 512 - 513









View 514 - 517












412-647-2130


johnsonjtupmcedu

CS37 Fax Number

412-647-2080


No


No

View CS040

Cover Sheet Section





View CS050 - CS063

Cover Sheet Section




Christine Harrison




412-232-9097





View CS070

Cover Sheet Section


No





View CS080

Cover Sheet Section






View CS090 - 100

Cover Sheet Section


No



No








View CS110

Cover Sheet Section



NameModified Date



No

View CS120 - 140

Cover Sheet Section


No























No



Yes



Cover Sheet Section













Yes






View CS160

Cover Sheet Section


CategoriesNone

View CS170

Cover Sheet Section


No













View 201



No







View 202



Yes


No








Yes





No








No

View 204



No






View 205



No



Addressed below


View 206


















No






View 207 - 207(b)





Yes




View 208



Yes







View 209 - 210



yes



View 211




View 212



No






View 213 HB



No








View 214





Yes









No





Yes


No

View 215



No








View 216



No




View 217 - 218








Addressed below





View 219 - 2196



No













View 221



No




NameModified Date

View 301 - 304(a)



18 and older







No



Yes




View 305 - 305(a)



No


















45 CFR 46406


45 CFR 46407



View 306



No















View 307



No











View 308



No















View 309



No








View 310 - 312(a)---gt




100











50 0




View 313 - 315(a)









No





Advertisements


Honest Broker








Research Registry







No















No


































View 408






No






View 410



Yes









View 411 - 411(b)








View 412 - 414(a)













Yes









View

ResearchActivity


CommonRisks

No Value Entered

InfrequentRisks





View

ResearchActivity

Questionnaires

CommonRisks

No Value Entered

InfrequentRisks



View

ResearchActivity

tongue exercises

CommonRisks


InfrequentRisks

No Value Entered









Addressed below



View 504



No




View 505



No




defects


View 506 - 506(a)





View 507 - 507(a)



Describe below



View 508 -508(a)






Yes







No



View 512 - 513









View 514 - 517












Christine Harrison




412-232-9097





View CS070

Cover Sheet Section


No





View CS080

Cover Sheet Section






View CS090 - 100

Cover Sheet Section


No



No








View CS110

Cover Sheet Section



NameModified Date



No

View CS120 - 140

Cover Sheet Section


No























No



Yes



Cover Sheet Section













Yes






View CS160

Cover Sheet Section


CategoriesNone

View CS170

Cover Sheet Section


No













View 201



No







View 202



Yes


No








Yes





No








No

View 204



No






View 205



No



Addressed below


View 206


















No






View 207 - 207(b)





Yes




View 208



Yes







View 209 - 210



yes



View 211




View 212



No






View 213 HB



No








View 214





Yes









No





Yes


No

View 215



No








View 216



No




View 217 - 218








Addressed below





View 219 - 2196



No













View 221



No




NameModified Date

View 301 - 304(a)



18 and older







No



Yes




View 305 - 305(a)



No


















45 CFR 46406


45 CFR 46407



View 306



No















View 307



No











View 308



No















View 309



No








View 310 - 312(a)---gt




100











50 0




View 313 - 315(a)









No





Advertisements


Honest Broker








Research Registry







No















No


































View 408






No






View 410



Yes









View 411 - 411(b)








View 412 - 414(a)













Yes









View

ResearchActivity


CommonRisks

No Value Entered

InfrequentRisks





View

ResearchActivity

Questionnaires

CommonRisks

No Value Entered

InfrequentRisks



View

ResearchActivity

tongue exercises

CommonRisks


InfrequentRisks

No Value Entered









Addressed below



View 504



No




View 505



No




defects


View 506 - 506(a)





View 507 - 507(a)



Describe below



View 508 -508(a)






Yes







No



View 512 - 513









View 514 - 517











View CS080

Cover Sheet Section






View CS090 - 100

Cover Sheet Section


No



No








View CS110

Cover Sheet Section



NameModified Date



No

View CS120 - 140

Cover Sheet Section


No























No



Yes



Cover Sheet Section













Yes






View CS160

Cover Sheet Section


CategoriesNone

View CS170

Cover Sheet Section


No













View 201



No







View 202



Yes


No








Yes





No








No

View 204



No






View 205



No



Addressed below


View 206


















No






View 207 - 207(b)





Yes




View 208



Yes







View 209 - 210



yes



View 211




View 212



No






View 213 HB



No








View 214





Yes









No





Yes


No

View 215



No








View 216



No




View 217 - 218








Addressed below





View 219 - 2196



No













View 221



No




NameModified Date

View 301 - 304(a)



18 and older







No



Yes




View 305 - 305(a)



No


















45 CFR 46406


45 CFR 46407



View 306



No















View 307



No











View 308



No















View 309



No








View 310 - 312(a)---gt




100











50 0




View 313 - 315(a)









No





Advertisements


Honest Broker








Research Registry







No















No


































View 408






No






View 410



Yes









View 411 - 411(b)








View 412 - 414(a)













Yes









View

ResearchActivity


CommonRisks

No Value Entered

InfrequentRisks





View

ResearchActivity

Questionnaires

CommonRisks

No Value Entered

InfrequentRisks



View

ResearchActivity

tongue exercises

CommonRisks


InfrequentRisks

No Value Entered









Addressed below



View 504



No




View 505



No




defects


View 506 - 506(a)





View 507 - 507(a)



Describe below



View 508 -508(a)






Yes







No



View 512 - 513









View 514 - 517













View CS110

Cover Sheet Section



NameModified Date



No

View CS120 - 140

Cover Sheet Section


No























No



Yes



Cover Sheet Section













Yes






View CS160

Cover Sheet Section


CategoriesNone

View CS170

Cover Sheet Section


No













View 201



No







View 202



Yes


No








Yes





No








No

View 204



No






View 205



No



Addressed below


View 206


















No






View 207 - 207(b)





Yes




View 208



Yes







View 209 - 210



yes



View 211




View 212



No






View 213 HB



No








View 214





Yes









No





Yes


No

View 215



No








View 216



No




View 217 - 218








Addressed below





View 219 - 2196



No













View 221



No




NameModified Date

View 301 - 304(a)



18 and older







No



Yes




View 305 - 305(a)



No


















45 CFR 46406


45 CFR 46407



View 306



No















View 307



No











View 308



No















View 309



No








View 310 - 312(a)---gt




100











50 0




View 313 - 315(a)









No





Advertisements


Honest Broker








Research Registry







No















No


































View 408






No






View 410



Yes









View 411 - 411(b)








View 412 - 414(a)













Yes









View

ResearchActivity


CommonRisks

No Value Entered

InfrequentRisks





View

ResearchActivity

Questionnaires

CommonRisks

No Value Entered

InfrequentRisks



View

ResearchActivity

tongue exercises

CommonRisks


InfrequentRisks

No Value Entered









Addressed below



View 504



No




View 505



No




defects


View 506 - 506(a)





View 507 - 507(a)



Describe below



View 508 -508(a)






Yes







No



View 512 - 513









View 514 - 517





























No



Yes



Cover Sheet Section













Yes






View CS160

Cover Sheet Section


CategoriesNone

View CS170

Cover Sheet Section


No













View 201



No







View 202



Yes


No








Yes





No








No

View 204



No






View 205



No



Addressed below


View 206


















No






View 207 - 207(b)





Yes




View 208



Yes







View 209 - 210



yes



View 211




View 212



No






View 213 HB



No








View 214





Yes









No





Yes


No

View 215



No








View 216



No




View 217 - 218








Addressed below





View 219 - 2196



No













View 221



No




NameModified Date

View 301 - 304(a)



18 and older







No



Yes




View 305 - 305(a)



No


















45 CFR 46406


45 CFR 46407



View 306



No















View 307



No











View 308



No















View 309



No








View 310 - 312(a)---gt




100











50 0




View 313 - 315(a)









No





Advertisements


Honest Broker








Research Registry







No















No


































View 408






No






View 410



Yes









View 411 - 411(b)








View 412 - 414(a)













Yes









View

ResearchActivity


CommonRisks

No Value Entered

InfrequentRisks





View

ResearchActivity

Questionnaires

CommonRisks

No Value Entered

InfrequentRisks



View

ResearchActivity

tongue exercises

CommonRisks


InfrequentRisks

No Value Entered









Addressed below



View 504



No




View 505



No




defects


View 506 - 506(a)





View 507 - 507(a)



Describe below



View 508 -508(a)






Yes







No



View 512 - 513









View 514 - 517


















Yes






View CS160

Cover Sheet Section


CategoriesNone

View CS170

Cover Sheet Section


No













View 201



No







View 202



Yes


No








Yes





No








No

View 204



No






View 205



No



Addressed below


View 206


















No






View 207 - 207(b)





Yes




View 208



Yes







View 209 - 210



yes



View 211




View 212



No






View 213 HB



No








View 214





Yes









No





Yes


No

View 215



No








View 216



No




View 217 - 218








Addressed below





View 219 - 2196



No













View 221



No




NameModified Date

View 301 - 304(a)



18 and older







No



Yes




View 305 - 305(a)



No


















45 CFR 46406


45 CFR 46407



View 306



No















View 307



No











View 308



No















View 309



No








View 310 - 312(a)---gt




100











50 0




View 313 - 315(a)









No





Advertisements


Honest Broker








Research Registry







No















No


































View 408






No






View 410



Yes









View 411 - 411(b)








View 412 - 414(a)













Yes









View

ResearchActivity


CommonRisks

No Value Entered

InfrequentRisks





View

ResearchActivity

Questionnaires

CommonRisks

No Value Entered

InfrequentRisks



View

ResearchActivity

tongue exercises

CommonRisks


InfrequentRisks

No Value Entered









Addressed below



View 504



No




View 505



No




defects


View 506 - 506(a)





View 507 - 507(a)



Describe below



View 508 -508(a)






Yes







No



View 512 - 513









View 514 - 517












View CS160

Cover Sheet Section


CategoriesNone

View CS170

Cover Sheet Section


No













View 201



No







View 202



Yes


No








Yes





No








No

View 204



No






View 205



No



Addressed below


View 206


















No






View 207 - 207(b)





Yes




View 208



Yes







View 209 - 210



yes



View 211




View 212



No






View 213 HB



No








View 214





Yes









No





Yes


No

View 215



No








View 216



No




View 217 - 218








Addressed below





View 219 - 2196



No













View 221



No




NameModified Date

View 301 - 304(a)



18 and older







No



Yes




View 305 - 305(a)



No


















45 CFR 46406


45 CFR 46407



View 306



No















View 307



No











View 308



No















View 309



No








View 310 - 312(a)---gt




100











50 0




View 313 - 315(a)









No





Advertisements


Honest Broker








Research Registry







No















No


































View 408






No






View 410



Yes









View 411 - 411(b)








View 412 - 414(a)













Yes









View

ResearchActivity


CommonRisks

No Value Entered

InfrequentRisks





View

ResearchActivity

Questionnaires

CommonRisks

No Value Entered

InfrequentRisks



View

ResearchActivity

tongue exercises

CommonRisks


InfrequentRisks

No Value Entered









Addressed below



View 504



No




View 505



No




defects


View 506 - 506(a)





View 507 - 507(a)



Describe below



View 508 -508(a)






Yes







No



View 512 - 513









View 514 - 517














View 201



No







View 202



Yes


No








Yes





No








No

View 204



No






View 205



No



Addressed below


View 206


















No






View 207 - 207(b)





Yes




View 208



Yes







View 209 - 210



yes



View 211




View 212



No






View 213 HB



No








View 214





Yes









No





Yes


No

View 215



No








View 216



No




View 217 - 218








Addressed below





View 219 - 2196



No













View 221



No




NameModified Date

View 301 - 304(a)



18 and older







No



Yes




View 305 - 305(a)



No


















45 CFR 46406


45 CFR 46407



View 306



No















View 307



No











View 308



No















View 309



No








View 310 - 312(a)---gt




100











50 0




View 313 - 315(a)









No





Advertisements


Honest Broker








Research Registry







No















No


































View 408






No






View 410



Yes









View 411 - 411(b)








View 412 - 414(a)













Yes









View

ResearchActivity


CommonRisks

No Value Entered

InfrequentRisks





View

ResearchActivity

Questionnaires

CommonRisks

No Value Entered

InfrequentRisks



View

ResearchActivity

tongue exercises

CommonRisks


InfrequentRisks

No Value Entered









Addressed below



View 504



No




View 505



No




defects


View 506 - 506(a)





View 507 - 507(a)



Describe below



View 508 -508(a)






Yes







No



View 512 - 513









View 514 - 517












View 202



Yes


No








Yes





No








No

View 204



No






View 205



No



Addressed below


View 206


















No






View 207 - 207(b)





Yes




View 208



Yes







View 209 - 210



yes



View 211




View 212



No






View 213 HB



No








View 214





Yes









No





Yes


No

View 215



No








View 216



No




View 217 - 218








Addressed below





View 219 - 2196



No













View 221



No




NameModified Date

View 301 - 304(a)



18 and older







No



Yes




View 305 - 305(a)



No


















45 CFR 46406


45 CFR 46407



View 306



No















View 307



No











View 308



No















View 309



No








View 310 - 312(a)---gt




100











50 0




View 313 - 315(a)









No





Advertisements


Honest Broker








Research Registry







No















No


































View 408






No






View 410



Yes









View 411 - 411(b)








View 412 - 414(a)













Yes









View

ResearchActivity


CommonRisks

No Value Entered

InfrequentRisks





View

ResearchActivity

Questionnaires

CommonRisks

No Value Entered

InfrequentRisks



View

ResearchActivity

tongue exercises

CommonRisks


InfrequentRisks

No Value Entered









Addressed below



View 504



No




View 505



No




defects


View 506 - 506(a)





View 507 - 507(a)



Describe below



View 508 -508(a)






Yes







No



View 512 - 513









View 514 - 517












No








No

View 204



No






View 205



No



Addressed below


View 206


















No






View 207 - 207(b)





Yes




View 208



Yes







View 209 - 210



yes



View 211




View 212



No






View 213 HB



No








View 214





Yes









No





Yes


No

View 215



No








View 216



No




View 217 - 218








Addressed below





View 219 - 2196



No













View 221



No




NameModified Date

View 301 - 304(a)



18 and older







No



Yes




View 305 - 305(a)



No


















45 CFR 46406


45 CFR 46407



View 306



No















View 307



No











View 308



No















View 309



No








View 310 - 312(a)---gt




100











50 0




View 313 - 315(a)









No





Advertisements


Honest Broker








Research Registry







No















No


































View 408






No






View 410



Yes









View 411 - 411(b)








View 412 - 414(a)













Yes









View

ResearchActivity


CommonRisks

No Value Entered

InfrequentRisks





View

ResearchActivity

Questionnaires

CommonRisks

No Value Entered

InfrequentRisks



View

ResearchActivity

tongue exercises

CommonRisks


InfrequentRisks

No Value Entered









Addressed below



View 504



No




View 505



No




defects


View 506 - 506(a)





View 507 - 507(a)



Describe below



View 508 -508(a)






Yes







No



View 512 - 513









View 514 - 517













View 205



No



Addressed below


View 206


















No






View 207 - 207(b)





Yes




View 208



Yes







View 209 - 210



yes



View 211




View 212



No






View 213 HB



No








View 214





Yes









No





Yes


No

View 215



No








View 216



No




View 217 - 218








Addressed below





View 219 - 2196



No













View 221



No




NameModified Date

View 301 - 304(a)



18 and older







No



Yes




View 305 - 305(a)



No


















45 CFR 46406


45 CFR 46407



View 306



No















View 307



No











View 308



No















View 309



No








View 310 - 312(a)---gt




100











50 0




View 313 - 315(a)









No





Advertisements


Honest Broker








Research Registry







No















No


































View 408






No






View 410



Yes









View 411 - 411(b)








View 412 - 414(a)













Yes









View

ResearchActivity


CommonRisks

No Value Entered

InfrequentRisks





View

ResearchActivity

Questionnaires

CommonRisks

No Value Entered

InfrequentRisks



View

ResearchActivity

tongue exercises

CommonRisks


InfrequentRisks

No Value Entered









Addressed below



View 504



No




View 505



No




defects


View 506 - 506(a)





View 507 - 507(a)



Describe below



View 508 -508(a)






Yes







No



View 512 - 513









View 514 - 517






















No






View 207 - 207(b)





Yes




View 208



Yes







View 209 - 210



yes



View 211




View 212



No






View 213 HB



No








View 214





Yes









No





Yes


No

View 215



No








View 216



No




View 217 - 218








Addressed below





View 219 - 2196



No













View 221



No




NameModified Date

View 301 - 304(a)



18 and older







No



Yes




View 305 - 305(a)



No


















45 CFR 46406


45 CFR 46407



View 306



No















View 307



No











View 308



No















View 309



No








View 310 - 312(a)---gt




100











50 0




View 313 - 315(a)









No





Advertisements


Honest Broker








Research Registry







No















No


































View 408






No






View 410



Yes









View 411 - 411(b)








View 412 - 414(a)













Yes









View

ResearchActivity


CommonRisks

No Value Entered

InfrequentRisks





View

ResearchActivity

Questionnaires

CommonRisks

No Value Entered

InfrequentRisks



View

ResearchActivity

tongue exercises

CommonRisks


InfrequentRisks

No Value Entered









Addressed below



View 504



No




View 505



No




defects


View 506 - 506(a)





View 507 - 507(a)



Describe below



View 508 -508(a)






Yes







No



View 512 - 513









View 514 - 517












Yes




View 208



Yes







View 209 - 210



yes



View 211




View 212



No






View 213 HB



No








View 214





Yes









No





Yes


No

View 215



No








View 216



No




View 217 - 218








Addressed below





View 219 - 2196



No













View 221



No




NameModified Date

View 301 - 304(a)



18 and older







No



Yes




View 305 - 305(a)



No


















45 CFR 46406


45 CFR 46407



View 306



No















View 307



No











View 308



No















View 309



No








View 310 - 312(a)---gt




100











50 0




View 313 - 315(a)









No





Advertisements


Honest Broker








Research Registry







No















No


































View 408






No






View 410



Yes









View 411 - 411(b)








View 412 - 414(a)













Yes









View

ResearchActivity


CommonRisks

No Value Entered

InfrequentRisks





View

ResearchActivity

Questionnaires

CommonRisks

No Value Entered

InfrequentRisks



View

ResearchActivity

tongue exercises

CommonRisks


InfrequentRisks

No Value Entered









Addressed below



View 504



No




View 505



No




defects


View 506 - 506(a)





View 507 - 507(a)



Describe below



View 508 -508(a)






Yes







No



View 512 - 513









View 514 - 517












View 209 - 210



yes



View 211




View 212



No






View 213 HB



No








View 214





Yes









No





Yes


No

View 215



No








View 216



No




View 217 - 218








Addressed below





View 219 - 2196



No













View 221



No




NameModified Date

View 301 - 304(a)



18 and older







No



Yes




View 305 - 305(a)



No


















45 CFR 46406


45 CFR 46407



View 306



No















View 307



No











View 308



No















View 309



No








View 310 - 312(a)---gt




100











50 0




View 313 - 315(a)









No





Advertisements


Honest Broker








Research Registry







No















No


































View 408






No






View 410



Yes









View 411 - 411(b)








View 412 - 414(a)













Yes









View

ResearchActivity


CommonRisks

No Value Entered

InfrequentRisks





View

ResearchActivity

Questionnaires

CommonRisks

No Value Entered

InfrequentRisks



View

ResearchActivity

tongue exercises

CommonRisks


InfrequentRisks

No Value Entered









Addressed below



View 504



No




View 505



No




defects


View 506 - 506(a)





View 507 - 507(a)



Describe below



View 508 -508(a)






Yes







No



View 512 - 513









View 514 - 517













View 213 HB



No








View 214





Yes









No





Yes


No

View 215



No








View 216



No




View 217 - 218








Addressed below





View 219 - 2196



No













View 221



No




NameModified Date

View 301 - 304(a)



18 and older







No



Yes




View 305 - 305(a)



No


















45 CFR 46406


45 CFR 46407



View 306



No















View 307



No











View 308



No















View 309



No








View 310 - 312(a)---gt




100











50 0




View 313 - 315(a)









No





Advertisements


Honest Broker








Research Registry







No















No


































View 408






No






View 410



Yes









View 411 - 411(b)








View 412 - 414(a)













Yes









View

ResearchActivity


CommonRisks

No Value Entered

InfrequentRisks





View

ResearchActivity

Questionnaires

CommonRisks

No Value Entered

InfrequentRisks



View

ResearchActivity

tongue exercises

CommonRisks


InfrequentRisks

No Value Entered









Addressed below



View 504



No




View 505



No




defects


View 506 - 506(a)





View 507 - 507(a)



Describe below



View 508 -508(a)






Yes







No



View 512 - 513









View 514 - 517











Yes









No





Yes


No

View 215



No








View 216



No




View 217 - 218








Addressed below





View 219 - 2196



No













View 221



No




NameModified Date

View 301 - 304(a)



18 and older







No



Yes




View 305 - 305(a)



No


















45 CFR 46406


45 CFR 46407



View 306



No















View 307



No











View 308



No















View 309



No








View 310 - 312(a)---gt




100











50 0




View 313 - 315(a)









No





Advertisements


Honest Broker








Research Registry







No















No


































View 408






No






View 410



Yes









View 411 - 411(b)








View 412 - 414(a)













Yes









View

ResearchActivity


CommonRisks

No Value Entered

InfrequentRisks





View

ResearchActivity

Questionnaires

CommonRisks

No Value Entered

InfrequentRisks



View

ResearchActivity

tongue exercises

CommonRisks


InfrequentRisks

No Value Entered









Addressed below



View 504



No




View 505



No




defects


View 506 - 506(a)





View 507 - 507(a)



Describe below



View 508 -508(a)






Yes







No



View 512 - 513









View 514 - 517













Yes


No

View 215



No








View 216



No




View 217 - 218








Addressed below





View 219 - 2196



No













View 221



No




NameModified Date

View 301 - 304(a)



18 and older







No



Yes




View 305 - 305(a)



No


















45 CFR 46406


45 CFR 46407



View 306



No















View 307



No











View 308



No















View 309



No








View 310 - 312(a)---gt




100











50 0




View 313 - 315(a)









No





Advertisements


Honest Broker








Research Registry







No















No


































View 408






No






View 410



Yes









View 411 - 411(b)








View 412 - 414(a)













Yes









View

ResearchActivity


CommonRisks

No Value Entered

InfrequentRisks





View

ResearchActivity

Questionnaires

CommonRisks

No Value Entered

InfrequentRisks



View

ResearchActivity

tongue exercises

CommonRisks


InfrequentRisks

No Value Entered









Addressed below



View 504



No




View 505



No




defects


View 506 - 506(a)





View 507 - 507(a)



Describe below



View 508 -508(a)






Yes







No



View 512 - 513









View 514 - 517











View 216



No




View 217 - 218








Addressed below





View 219 - 2196



No













View 221



No




NameModified Date

View 301 - 304(a)



18 and older







No



Yes




View 305 - 305(a)



No


















45 CFR 46406


45 CFR 46407



View 306



No















View 307



No











View 308



No















View 309



No








View 310 - 312(a)---gt




100











50 0




View 313 - 315(a)









No





Advertisements


Honest Broker








Research Registry







No















No


































View 408






No






View 410



Yes









View 411 - 411(b)








View 412 - 414(a)













Yes









View

ResearchActivity


CommonRisks

No Value Entered

InfrequentRisks





View

ResearchActivity

Questionnaires

CommonRisks

No Value Entered

InfrequentRisks



View

ResearchActivity

tongue exercises

CommonRisks


InfrequentRisks

No Value Entered









Addressed below



View 504



No




View 505



No




defects


View 506 - 506(a)





View 507 - 507(a)



Describe below



View 508 -508(a)






Yes







No



View 512 - 513









View 514 - 517













Addressed below





View 219 - 2196



No













View 221



No




NameModified Date

View 301 - 304(a)



18 and older







No



Yes




View 305 - 305(a)



No


















45 CFR 46406


45 CFR 46407



View 306



No















View 307



No











View 308



No















View 309



No








View 310 - 312(a)---gt




100











50 0




View 313 - 315(a)









No





Advertisements


Honest Broker








Research Registry







No















No


































View 408






No






View 410



Yes









View 411 - 411(b)








View 412 - 414(a)













Yes









View

ResearchActivity


CommonRisks

No Value Entered

InfrequentRisks





View

ResearchActivity

Questionnaires

CommonRisks

No Value Entered

InfrequentRisks



View

ResearchActivity

tongue exercises

CommonRisks


InfrequentRisks

No Value Entered









Addressed below



View 504



No




View 505



No




defects


View 506 - 506(a)





View 507 - 507(a)



Describe below



View 508 -508(a)






Yes







No



View 512 - 513









View 514 - 517




















View 221



No




NameModified Date

View 301 - 304(a)



18 and older







No



Yes




View 305 - 305(a)



No


















45 CFR 46406


45 CFR 46407



View 306



No















View 307



No











View 308



No















View 309



No








View 310 - 312(a)---gt




100











50 0




View 313 - 315(a)









No





Advertisements


Honest Broker








Research Registry







No















No


































View 408






No






View 410



Yes









View 411 - 411(b)








View 412 - 414(a)













Yes









View

ResearchActivity


CommonRisks

No Value Entered

InfrequentRisks





View

ResearchActivity

Questionnaires

CommonRisks

No Value Entered

InfrequentRisks



View

ResearchActivity

tongue exercises

CommonRisks


InfrequentRisks

No Value Entered









Addressed below



View 504



No




View 505



No




defects


View 506 - 506(a)





View 507 - 507(a)



Describe below



View 508 -508(a)






Yes







No



View 512 - 513









View 514 - 517















No



Yes




View 305 - 305(a)



No


















45 CFR 46406


45 CFR 46407



View 306



No















View 307



No











View 308



No















View 309



No








View 310 - 312(a)---gt




100











50 0




View 313 - 315(a)









No





Advertisements


Honest Broker








Research Registry







No















No


































View 408






No






View 410



Yes









View 411 - 411(b)








View 412 - 414(a)













Yes









View

ResearchActivity


CommonRisks

No Value Entered

InfrequentRisks





View

ResearchActivity

Questionnaires

CommonRisks

No Value Entered

InfrequentRisks



View

ResearchActivity

tongue exercises

CommonRisks


InfrequentRisks

No Value Entered









Addressed below



View 504



No




View 505



No




defects


View 506 - 506(a)





View 507 - 507(a)



Describe below



View 508 -508(a)






Yes







No



View 512 - 513









View 514 - 517
























45 CFR 46406


45 CFR 46407



View 306



No















View 307



No











View 308



No















View 309



No








View 310 - 312(a)---gt




100











50 0




View 313 - 315(a)









No





Advertisements


Honest Broker








Research Registry







No















No


































View 408






No






View 410



Yes









View 411 - 411(b)








View 412 - 414(a)













Yes









View

ResearchActivity


CommonRisks

No Value Entered

InfrequentRisks





View

ResearchActivity

Questionnaires

CommonRisks

No Value Entered

InfrequentRisks



View

ResearchActivity

tongue exercises

CommonRisks


InfrequentRisks

No Value Entered









Addressed below



View 504



No




View 505



No




defects


View 506 - 506(a)





View 507 - 507(a)



Describe below



View 508 -508(a)






Yes







No



View 512 - 513









View 514 - 517






















View 307



No











View 308



No















View 309



No








View 310 - 312(a)---gt




100











50 0




View 313 - 315(a)









No





Advertisements


Honest Broker








Research Registry







No















No


































View 408






No






View 410



Yes









View 411 - 411(b)








View 412 - 414(a)













Yes









View

ResearchActivity


CommonRisks

No Value Entered

InfrequentRisks





View

ResearchActivity

Questionnaires

CommonRisks

No Value Entered

InfrequentRisks



View

ResearchActivity

tongue exercises

CommonRisks


InfrequentRisks

No Value Entered









Addressed below



View 504



No




View 505



No




defects


View 506 - 506(a)





View 507 - 507(a)



Describe below



View 508 -508(a)






Yes







No



View 512 - 513









View 514 - 517













View 308



No















View 309



No








View 310 - 312(a)---gt




100











50 0




View 313 - 315(a)









No





Advertisements


Honest Broker








Research Registry







No















No


































View 408






No






View 410



Yes









View 411 - 411(b)








View 412 - 414(a)













Yes









View

ResearchActivity


CommonRisks

No Value Entered

InfrequentRisks





View

ResearchActivity

Questionnaires

CommonRisks

No Value Entered

InfrequentRisks



View

ResearchActivity

tongue exercises

CommonRisks


InfrequentRisks

No Value Entered









Addressed below



View 504



No




View 505



No




defects


View 506 - 506(a)





View 507 - 507(a)



Describe below



View 508 -508(a)






Yes







No



View 512 - 513









View 514 - 517
















View 309



No








View 310 - 312(a)---gt




100











50 0




View 313 - 315(a)









No





Advertisements


Honest Broker








Research Registry







No















No


































View 408






No






View 410



Yes









View 411 - 411(b)








View 412 - 414(a)













Yes









View

ResearchActivity


CommonRisks

No Value Entered

InfrequentRisks





View

ResearchActivity

Questionnaires

CommonRisks

No Value Entered

InfrequentRisks



View

ResearchActivity

tongue exercises

CommonRisks


InfrequentRisks

No Value Entered









Addressed below



View 504



No




View 505



No




defects


View 506 - 506(a)





View 507 - 507(a)



Describe below



View 508 -508(a)






Yes







No



View 512 - 513









View 514 - 517















View 310 - 312(a)---gt




100











50 0




View 313 - 315(a)









No





Advertisements


Honest Broker








Research Registry







No















No


































View 408






No






View 410



Yes









View 411 - 411(b)








View 412 - 414(a)













Yes









View

ResearchActivity


CommonRisks

No Value Entered

InfrequentRisks





View

ResearchActivity

Questionnaires

CommonRisks

No Value Entered

InfrequentRisks



View

ResearchActivity

tongue exercises

CommonRisks


InfrequentRisks

No Value Entered









Addressed below



View 504



No




View 505



No




defects


View 506 - 506(a)





View 507 - 507(a)



Describe below



View 508 -508(a)






Yes







No



View 512 - 513









View 514 - 517















50 0




View 313 - 315(a)









No





Advertisements


Honest Broker








Research Registry







No















No


































View 408






No






View 410



Yes









View 411 - 411(b)








View 412 - 414(a)













Yes









View

ResearchActivity


CommonRisks

No Value Entered

InfrequentRisks





View

ResearchActivity

Questionnaires

CommonRisks

No Value Entered

InfrequentRisks



View

ResearchActivity

tongue exercises

CommonRisks


InfrequentRisks

No Value Entered









Addressed below



View 504



No




View 505



No




defects


View 506 - 506(a)





View 507 - 507(a)



Describe below



View 508 -508(a)






Yes







No



View 512 - 513









View 514 - 517












No





Advertisements


Honest Broker








Research Registry







No















No


































View 408






No






View 410



Yes









View 411 - 411(b)








View 412 - 414(a)













Yes









View

ResearchActivity


CommonRisks

No Value Entered

InfrequentRisks





View

ResearchActivity

Questionnaires

CommonRisks

No Value Entered

InfrequentRisks



View

ResearchActivity

tongue exercises

CommonRisks


InfrequentRisks

No Value Entered









Addressed below



View 504



No




View 505



No




defects


View 506 - 506(a)





View 507 - 507(a)



Describe below



View 508 -508(a)






Yes







No



View 512 - 513









View 514 - 517











Research Registry







No















No


































View 408






No






View 410



Yes









View 411 - 411(b)








View 412 - 414(a)













Yes









View

ResearchActivity


CommonRisks

No Value Entered

InfrequentRisks





View

ResearchActivity

Questionnaires

CommonRisks

No Value Entered

InfrequentRisks



View

ResearchActivity

tongue exercises

CommonRisks


InfrequentRisks

No Value Entered









Addressed below



View 504



No




View 505



No




defects


View 506 - 506(a)





View 507 - 507(a)



Describe below



View 508 -508(a)






Yes







No



View 512 - 513









View 514 - 517




















No


































View 408






No






View 410



Yes









View 411 - 411(b)








View 412 - 414(a)













Yes









View

ResearchActivity


CommonRisks

No Value Entered

InfrequentRisks





View

ResearchActivity

Questionnaires

CommonRisks

No Value Entered

InfrequentRisks



View

ResearchActivity

tongue exercises

CommonRisks


InfrequentRisks

No Value Entered









Addressed below



View 504



No




View 505



No




defects


View 506 - 506(a)





View 507 - 507(a)



Describe below



View 508 -508(a)






Yes







No



View 512 - 513









View 514 - 517







































View 408






No






View 410



Yes









View 411 - 411(b)








View 412 - 414(a)













Yes









View

ResearchActivity


CommonRisks

No Value Entered

InfrequentRisks





View

ResearchActivity

Questionnaires

CommonRisks

No Value Entered

InfrequentRisks



View

ResearchActivity

tongue exercises

CommonRisks


InfrequentRisks

No Value Entered









Addressed below



View 504



No




View 505



No




defects


View 506 - 506(a)





View 507 - 507(a)



Describe below



View 508 -508(a)






Yes







No



View 512 - 513









View 514 - 517














No






View 410



Yes









View 411 - 411(b)








View 412 - 414(a)













Yes









View

ResearchActivity


CommonRisks

No Value Entered

InfrequentRisks





View

ResearchActivity

Questionnaires

CommonRisks

No Value Entered

InfrequentRisks



View

ResearchActivity

tongue exercises

CommonRisks


InfrequentRisks

No Value Entered









Addressed below



View 504



No




View 505



No




defects


View 506 - 506(a)





View 507 - 507(a)



Describe below



View 508 -508(a)






Yes







No



View 512 - 513









View 514 - 517















View 411 - 411(b)








View 412 - 414(a)













Yes









View

ResearchActivity


CommonRisks

No Value Entered

InfrequentRisks





View

ResearchActivity

Questionnaires

CommonRisks

No Value Entered

InfrequentRisks



View

ResearchActivity

tongue exercises

CommonRisks


InfrequentRisks

No Value Entered









Addressed below



View 504



No




View 505



No




defects


View 506 - 506(a)





View 507 - 507(a)



Describe below



View 508 -508(a)






Yes







No



View 512 - 513









View 514 - 517




















Yes









View

ResearchActivity


CommonRisks

No Value Entered

InfrequentRisks





View

ResearchActivity

Questionnaires

CommonRisks

No Value Entered

InfrequentRisks



View

ResearchActivity

tongue exercises

CommonRisks


InfrequentRisks

No Value Entered









Addressed below



View 504



No




View 505



No




defects


View 506 - 506(a)





View 507 - 507(a)



Describe below



View 508 -508(a)






Yes







No



View 512 - 513









View 514 - 517

















View

ResearchActivity


CommonRisks

No Value Entered

InfrequentRisks





View

ResearchActivity

Questionnaires

CommonRisks

No Value Entered

InfrequentRisks



View

ResearchActivity

tongue exercises

CommonRisks


InfrequentRisks

No Value Entered









Addressed below



View 504



No




View 505



No




defects


View 506 - 506(a)





View 507 - 507(a)



Describe below



View 508 -508(a)






Yes







No



View 512 - 513









View 514 - 517











View

ResearchActivity

Questionnaires

CommonRisks

No Value Entered

InfrequentRisks



View

ResearchActivity

tongue exercises

CommonRisks


InfrequentRisks

No Value Entered









Addressed below



View 504



No




View 505



No




defects


View 506 - 506(a)





View 507 - 507(a)



Describe below



View 508 -508(a)






Yes







No



View 512 - 513









View 514 - 517













Addressed below



View 504



No




View 505



No




defects


View 506 - 506(a)





View 507 - 507(a)



Describe below



View 508 -508(a)






Yes







No



View 512 - 513









View 514 - 517











defects


View 506 - 506(a)





View 507 - 507(a)



Describe below



View 508 -508(a)






Yes







No



View 512 - 513









View 514 - 517












Yes







No



View 512 - 513









View 514 - 517














View 514 - 517









Pilot Study to Improve Therapeutic Outcomes for Dysphagia ... · Pilot Study to Improve Therapeutic...

Documents

Transcript of Pilot Study to Improve Therapeutic Outcomes for Dysphagia ... · Pilot Study to Improve Therapeutic...